HSBC Holdings’s Teva Pharmaceuticals TEVA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-10,700
Closed -$335K 3217
2025
Q4
$335K Sell
10,700
-177,900
-94% -$4.38M ﹤0.01% 2480
2025
Q3
$3.81M Buy
188,600
+54,500
+41% +$957K ﹤0.01% 1282
2025
Q2
$2.25M Sell
134,100
-54,500
-29% -$879K ﹤0.01% 1442
2025
Q1
$2.91M Buy
+188,600
New +$3.37M ﹤0.01% 1308
2019
Q2
Sell
-5,500
Closed -$86K 2853
2019
Q1
$86K Buy
+5,500
New +$97K ﹤0.01% 2635
2018
Q3
Sell
-179,700
Closed -$4.37M 2654
2018
Q2
$4.37M Buy
+179,700
New +$3.66M 0.01% 1185
2017
Q4
Sell
-300
Closed -$5K 2360
2017
Q3
$5K Sell
300
-2,700
-90% -$60.8K ﹤0.01% 2287
2017
Q2
$100K Buy
3,000
+900
+43% +$27.9K ﹤0.01% 2130
2017
Q1
$69K Hold
2,100
﹤0.01% 2075
2016
Q4
$76K Sell
2,100
-1,400
-40% -$55.9K ﹤0.01% 2643
2016
Q3
$161K Buy
+3,500
New +$183K ﹤0.01% 1965
2014
Q3
Sell
-6,000
Closed -$317K 1793
2014
Q2
$317K Sell
6,000
-5,000
-45% -$256K ﹤0.01% 1591
2014
Q1
$581K Buy
+11,000
New +$508K ﹤0.01% 1364

Other funds holding TEVA

HSBC Holdings's TEVA Position: Q2 2026 in Review

HSBC Holdings reduced its Teva Pharmaceuticals (TEVA) stake by 18% in Q2 2026, selling an estimated $5.85M and leaving 785,524 shares worth $26.6M. The position accounts for 0.01% of the portfolio, ranked #680.

HSBC Holdings first reported a position in TEVA in Q2 2013 and has held it in 53 quarters since. The position peaked at $29.9M in Q3 2025. 675 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • HSBC Holdings held 785,524 shares of Teva Pharmaceuticals worth $26.6M as of Q2 2026.
  • HSBC Holdings sold 175,616 Teva Pharmaceuticals shares in Q2 2026, an estimated $5.85M.
  • Teva Pharmaceuticals made up 0.01% of HSBC Holdings's portfolio in Q2 2026, its #680 holding.
  • HSBC Holdings first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
  • HSBC Holdings's Teva Pharmaceuticals position peaked at $29.9M in Q3 2025.
  • 675 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on HSBC Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.